@article{3116777,
    title = "Prognostic value of serum free light chain ratio at diagnosis in
multiple myeloma",
    author = "Kyrtsonis, Marie-Christine and Vassilakopoulos, Theodoros P. and Kafasi, and Nicoletta and Sachanas, Sotirios and Tzenou, Tatiana and Papadogiannis, and Argiroula and Galanis, Zacharoula and Kalpadakis, Christina and Dimou, and Maria and Kyriakou, Elias and Angelopoulou, Maria K. and Dimopoulou, and Maria N. and Siakantaris, Marina P. and Dimitriadou, Evangelia M. and and Kokoris, Styliani I. and Panayiotidis, Panayiotis and Pangalis, and Gerassimos A.",
    journal = "British Journal of Haematology",
    year = "2007",
    volume = "137",
    number = "3",
    pages = "240-243",
    publisher = "Wiley",
    issn = "0007-1048, 1365-2141",
    doi = "10.1111/j.1365-2141.2007.06561.x",
    keywords = "multiple myeloma; free light chain ratio; prognosis",
    abstract = "The prognostic value of baseline serum free light chain ratio (sFLCR)
was investigated in 94 multiple myeloma (MM) patients. sFLCR was
calculated as kappa/lambda or lambda/kappa, depending on the patients’
dominating monoclonal light chain. Median baseline sFLCR was 3.57 in
kappa-MM patients, 45.09 in lambda-MM. ‘High’ sFLCR (>= the observed
median value for kappa- and lambda-MM respectively) correlated with
elevated serum creatinine and lactate dehydrogenase, extensive marrow
infiltration and light chain type MM. The 5-year disease-specific
survival was 82% and 30% in patients with sFLCR lower than and equal
or greater than the median, respectively (P = 0.0001). sFLCR was an
independent prognostic factor."
}